Literature DB >> 26874851

Expression of ROR1 has prognostic significance in triple negative breast cancer.

Hui-Ping Chien, Shir-Hwa Ueng1, Shin-Cheh Chen2, Yu-Sun Chang3, Yung-Chang Lin4, Yun-Feng Lo2, Hsien-Kun Chang4, Wen-Yu Chuang1, Yi-Ting Huang5, Yun-Chung Cheung6, Shih-Che Shen2, Chuen Hsueh7,8.   

Abstract

Overexpression of receptor tyrosine kinase-like orphan receptor (ROR1) in a variety of human malignancies is associated with aggressive behaviour. Therapeutic agents targeting ROR1 have shown promising results in vivo and in vitro studies. In breast cancer, high-level expression of ROR1 mRNA is associated with high-grade tumours and metastasis. We investigated the prevalence and prognostic significance of ROR1 expression in triple negative breast cancer (TNBC). ROR1 was immunohistochemically stained on full-face sections of 210 TNBC patient samples. Forty-seven TNBC cases (22.4 %) showed strong ROR1 expression, which was associated with shorter disease-free survival (DFS; P = 0.00015), distant metastasis-free survival (DMFS; P = 0.00013) and overall survival (OS; P = 0.026) in univariate analyses. Results were confirmed by multivariate analysis. Seventy TNBC cases (33.3 %) with medullary features showed longer OS (P = 0.00013). We divided the whole series into two subgroups based on the presence or absence of medullary features. Strong ROR1 expression retained a predictive value of shorter DFS and DMFS in both subgroups. Our study suggests that strong ROR1 expression might be an independent adverse prognostic factor in TNBC patients and may serve as a potential marker for patient selection in ROR1-targeted therapy. More large-scale studies are needed to clarify its potential usefulness.

Entities:  

Keywords:  Carcinoma with medullary features; Prognosis; ROR1 tyrosine kinase; Triple negative breast cancer

Mesh:

Substances:

Year:  2016        PMID: 26874851     DOI: 10.1007/s00428-016-1911-3

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  23 in total

1.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies.

Authors:  Brian D Lehmann; Joshua A Bauer; Xi Chen; Melinda E Sanders; A Bapsi Chakravarthy; Yu Shyr; Jennifer A Pietenpol
Journal:  J Clin Invest       Date:  2011-07       Impact factor: 14.808

2.  NKX2-1/TITF1/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma.

Authors:  Tomoya Yamaguchi; Kiyoshi Yanagisawa; Ryoji Sugiyama; Yasuyuki Hosono; Yukako Shimada; Chinatsu Arima; Seiichi Kato; Shuta Tomida; Motoshi Suzuki; Hirotaka Osada; Takashi Takahashi
Journal:  Cancer Cell       Date:  2012-03-20       Impact factor: 31.743

3.  Spatio-temporally regulated expression of receptor tyrosine kinases, mRor1, mRor2, during mouse development: implications in development and function of the nervous system.

Authors:  I Oishi; S Takeuchi; R Hashimoto; A Nagabukuro; T Ueda; Z J Liu; T Hatta; S Akira; Y Matsuda; H Yamamura; H Otani; Y Minami
Journal:  Genes Cells       Date:  1999-01       Impact factor: 1.891

4.  Molecular portraits of human breast tumours.

Authors:  C M Perou; T Sørlie; M B Eisen; M van de Rijn; S S Jeffrey; C A Rees; J R Pollack; D T Ross; H Johnsen; L A Akslen; O Fluge; A Pergamenschikov; C Williams; S X Zhu; P E Lønning; A L Børresen-Dale; P O Brown; D Botstein
Journal:  Nature       Date:  2000-08-17       Impact factor: 49.962

5.  Antisera induced by infusions of autologous Ad-CD154-leukemia B cells identify ROR1 as an oncofetal antigen and receptor for Wnt5a.

Authors:  Tetsuya Fukuda; Liguang Chen; Tomoyuki Endo; Li Tang; Desheng Lu; Januario E Castro; George F Widhopf; Laura Z Rassenti; Mark J Cantwell; Charles E Prussak; Dennis A Carson; Thomas J Kipps
Journal:  Proc Natl Acad Sci U S A       Date:  2008-02-19       Impact factor: 11.205

6.  Phosphorylated mTOR expression correlates with poor outcome in early-stage triple negative breast carcinomas.

Authors:  Shir-Hwa Ueng; Shin-Cheh Chen; Yu-Sun Chang; Swei Hsueh; Yung-Chang Lin; Hui-Ping Chien; Yun-Feng Lo; Shih-Che Shen; Chuen Hsueh
Journal:  Int J Clin Exp Pathol       Date:  2012-10-01

7.  Targeting ROR1 inhibits epithelial-mesenchymal transition and metastasis.

Authors:  Bing Cui; Suping Zhang; Liguang Chen; Jianqiang Yu; George F Widhopf; Jessie-F Fecteau; Laura Z Rassenti; Thomas J Kipps
Journal:  Cancer Res       Date:  2013-06-15       Impact factor: 12.701

8.  Hypoxia induces phenotypic plasticity and therapy resistance in melanoma via the tyrosine kinase receptors ROR1 and ROR2.

Authors:  Michael P O'Connell; Katie Marchbank; Marie R Webster; Alexander A Valiga; Amanpreet Kaur; Adina Vultur; Ling Li; Meenhard Herlyn; Jessie Villanueva; Qin Liu; Xiangfan Yin; Sandy Widura; Janelle Nelson; Nivia Ruiz; Tura C Camilli; Fred E Indig; Keith T Flaherty; Jennifer A Wargo; Dennie T Frederick; Zachary A Cooper; Suresh Nair; Ravi K Amaravadi; Lynn M Schuchter; Giorgos C Karakousis; Wei Xu; Xiaowei Xu; Ashani T Weeraratna
Journal:  Cancer Discov       Date:  2013-10-08       Impact factor: 39.397

9.  Unique cell surface expression of receptor tyrosine kinase ROR1 in human B-cell chronic lymphocytic leukemia.

Authors:  Sivasubramanian Baskar; Ka Yin Kwong; Thomas Hofer; Jessica M Levy; Michael G Kennedy; Elinor Lee; Louis M Staudt; Wyndham H Wilson; Adrian Wiestner; Christoph Rader
Journal:  Clin Cancer Res       Date:  2008-01-15       Impact factor: 12.531

10.  Inhibition of the receptor tyrosine kinase ROR1 by anti-ROR1 monoclonal antibodies and siRNA induced apoptosis of melanoma cells.

Authors:  Mohammad Hojjat-Farsangi; Fatemeh Ghaemimanesh; Amir Hossein Daneshmanesh; Ali-Ahmad Bayat; Jafar Mahmoudian; Mahmood Jeddi-Tehrani; Hodjatallah Rabbani; Hakan Mellstedt
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

View more
  25 in total

1.  Logic-Gated ROR1 Chimeric Antigen Receptor Expression Rescues T Cell-Mediated Toxicity to Normal Tissues and Enables Selective Tumor Targeting.

Authors:  Shivani Srivastava; Alexander I Salter; Denny Liggitt; Sushma Yechan-Gunja; Megha Sarvothama; Kirsten Cooper; Kimberly S Smythe; Jarrod A Dudakov; Robert H Pierce; Christoph Rader; Stanley R Riddell
Journal:  Cancer Cell       Date:  2019-03-18       Impact factor: 31.743

2.  Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues.

Authors:  Ashwini Balakrishnan; Tracy Goodpaster; Julie Randolph-Habecker; Benjamin G Hoffstrom; Florencia G Jalikis; Lisa K Koch; Carolina Berger; Paula L Kosasih; Anusha Rajan; Daniel Sommermeyer; Peggy L Porter; Stanley R Riddell
Journal:  Clin Cancer Res       Date:  2016-11-16       Impact factor: 12.531

3.  High-level ROR1 associates with accelerated disease progression in chronic lymphocytic leukemia.

Authors:  Bing Cui; Emanuela M Ghia; Liguang Chen; Laura Z Rassenti; Christopher DeBoever; George F Widhopf; Jian Yu; Donna S Neuberg; William G Wierda; Kanti R Rai; Neil E Kay; Jennifer R Brown; Jeffrey A Jones; John G Gribben; Kelly A Frazer; Thomas J Kipps
Journal:  Blood       Date:  2016-11-04       Impact factor: 22.113

Review 4.  The emerging role of Wnt5a in the promotion of a pro-inflammatory and immunosuppressive tumor microenvironment.

Authors:  Pablo Lopez-Bergami; Gastón Barbero
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

5.  Nanoparticles That Reshape the Tumor Milieu Create a Therapeutic Window for Effective T-cell Therapy in Solid Malignancies.

Authors:  Fan Zhang; Sirkka B Stephan; Chibawanye I Ene; Tyrel T Smith; Eric C Holland; Matthias T Stephan
Journal:  Cancer Res       Date:  2018-05-14       Impact factor: 12.701

Review 6.  Glucocorticoid Receptor: A Multifaceted Actor in Breast Cancer.

Authors:  Lara Malik Noureddine; Olivier Trédan; Nader Hussein; Bassam Badran; Muriel Le Romancer; Coralie Poulard
Journal:  Int J Mol Sci       Date:  2021-04-24       Impact factor: 5.923

7.  An ROR1 bi-specific T-cell engager provides effective targeting and cytotoxicity against a range of solid tumors.

Authors:  Satyen Harish Gohil; Solange Rosa Paredes-Moscosso; Micaela Harrasser; Marzia Vezzalini; Aldo Scarpa; Emma Morris; Andrew M Davidoff; Claudio Sorio; Amit Chunilal Nathwani; Marco Della Peruta
Journal:  Oncoimmunology       Date:  2017-05-17       Impact factor: 8.110

Review 8.  Wnt5a Signaling in Normal and Cancer Stem Cells.

Authors:  Yan Zhou; Thomas J Kipps; Suping Zhang
Journal:  Stem Cells Int       Date:  2017-04-12       Impact factor: 5.443

9.  Antitumor activity of a newly developed monoclonal antibody against ROR1 in ovarian cancer cells.

Authors:  Zhengna Yin; Mengyun Gao; Sasa Chu; Yiping Su; Chunping Ye; Yiquan Wang; Zhuanqin Pan; Zhuming Wang; Huilin Zhang; Hua Tong; Jin Zhu
Journal:  Oncotarget       Date:  2017-10-07

10.  Silencing ROR1 and ROR2 inhibits invasion and adhesion in an organotypic model of ovarian cancer metastasis.

Authors:  Claire Henry; Neville Hacker; Caroline Ford
Journal:  Oncotarget       Date:  2017-11-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.